• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

3.870 +0.270 (+7.50%)
Streaming Delayed Price Updated: 10:15 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 113,050
Open 3.725
Bid (Size) 3.810 (100)
Ask (Size) 3.870 (400)
Prev. Close 3.600
Today's Range 3.508 - 3.900
52wk Range 0.6101 - 4.220
Shares Outstanding 54,808,715
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
March 10, 2026
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
+41.8%
+41.8%
1 Month
+79.6%
+79.6%
3 Month
+127.6%
+127.6%
6 Month
+225.2%
+225.2%
1 Year
+477.6%
+477.6%

More News

Read More
News headline image
Why Did PRLD Stock Surge 13% Today? ↗
February 03, 2026
Via Stocktwits
News headline image
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
February 03, 2026
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
From Equity Insider
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
December 06, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
November 26, 2025
From Schall Law
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
November 19, 2025
From Schall Law
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
November 13, 2025
Via Benzinga
News headline image
Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗
November 12, 2025
Via Chartmill
News headline image
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
November 11, 2025
From The Schall Law Firm
Via Business Wire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
November 05, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
November 04, 2025
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
November 04, 2025
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
November 04, 2025
Via Chartmill
News headline image
Tuesday's session: top gainers and losers ↗
November 04, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
November 04, 2025
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
November 04, 2025
Via Chartmill
News headline image
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates ↗
November 04, 2025
Via Benzinga
Topics Stocks
News headline image
Tuesday's pre-market session: top gainers and losers ↗
November 04, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
November 04, 2025
Via Benzinga
News headline image
Prelude Therapeutics Announces Strategic Business Update
November 04, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire

Frequently Asked Questions

Is Prelude Therapeutics Incorporated - Common Stock publicly traded?
Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?
Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?
The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market
What is the current price of Prelude Therapeutics Incorporated - Common Stock?
The current price of Prelude Therapeutics Incorporated - Common Stock is 3.870
When was Prelude Therapeutics Incorporated - Common Stock last traded?
The last trade of Prelude Therapeutics Incorporated - Common Stock was at 03/11/26 10:15 AM ET
What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 212.11M
How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
Prelude Therapeutics Incorporated - Common Stock has 212M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap